AR105493A1 - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
AR105493A1
AR105493A1 ARP160102274A ARP160102274A AR105493A1 AR 105493 A1 AR105493 A1 AR 105493A1 AR P160102274 A ARP160102274 A AR P160102274A AR P160102274 A ARP160102274 A AR P160102274A AR 105493 A1 AR105493 A1 AR 105493A1
Authority
AR
Argentina
Prior art keywords
idh1
muted
inhibitor
adduct
isocitrate
Prior art date
Application number
ARP160102274A
Other languages
English (en)
Inventor
Dr Schirmer Heiko
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR105493A1 publication Critical patent/AR105493A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se relaciona con el aducto ácido (2E)-but-2-enedioico - ácido 3-(2-{[4-(trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-bencimidazol-5-il)propanoico (1:4), métodos para preparar este aducto, composiciones farmacéuticas que comprenden este aducto y también el uso de este aducto para preparar un medicamento o para el tratamiento de una enfermedad.
ARP160102274A 2015-07-27 2016-07-27 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h AR105493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27

Publications (1)

Publication Number Publication Date
AR105493A1 true AR105493A1 (es) 2017-10-11

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102274A AR105493A1 (es) 2015-07-27 2016-07-27 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160361A (es) 2014-02-11 2016-10-03 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2965213A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
US10370339B2 (en) 2015-06-08 2019-08-06 Bayer Pharma Aktiengesellschaft N-Methylbenzimidazoles as mIDH1 inhibitors
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
CA2992364A1 (en) 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
CA3189348A1 (en) 2020-07-21 2022-01-27 Daiichi Sankyo Company, Limited Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125901B2 (en) * 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
EP2771337B1 (en) * 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
CR20160361A (es) 2014-02-11 2016-10-03 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2965213A1 (en) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
ES2822654T3 (es) * 2014-10-23 2021-05-04 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Benzimidazol-2-aminas como inhibidores de mIDH1
US10370339B2 (en) * 2015-06-08 2019-08-06 Bayer Pharma Aktiengesellschaft N-Methylbenzimidazoles as mIDH1 inhibitors
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
CA2992364A1 (en) * 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
CN107810181A (zh) 2018-03-16
DOP2018000027A (es) 2018-02-28
TN2018000038A1 (en) 2019-07-08
US20180222870A1 (en) 2018-08-09
ES2860693T3 (es) 2021-10-05
AU2016300980A1 (en) 2017-12-21
KR20180030789A (ko) 2018-03-26
BR112018001534A2 (pt) 2018-09-11
AU2016300980B2 (en) 2020-12-24
IL256024A (en) 2018-01-31
CN107810181B (zh) 2021-06-22
HK1252449A1 (zh) 2019-05-24
CO2018000793A2 (es) 2018-05-10
ECSP18006465A (es) 2018-04-30
JP2018521095A (ja) 2018-08-02
CU20180014A7 (es) 2018-06-05
EP3328837A1 (en) 2018-06-06
NI201800014A (es) 2018-09-06
JP6804516B2 (ja) 2020-12-23
SV2018005621A (es) 2018-12-05
WO2017016992A1 (en) 2017-02-02
US10344004B2 (en) 2019-07-09
TW201708193A (zh) 2017-03-01
EA201890386A1 (ru) 2018-08-31
CR20180053A (es) 2018-03-20
PE20181038A1 (es) 2018-07-03
CA2993473A1 (en) 2017-02-02
EP3328837B1 (en) 2021-01-06
MX2018001205A (es) 2018-04-24
CL2018000249A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
AR105493A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CR20170242A (es) Benzamidas sustituidas copn 1,3-tiazol-2-ilo
EA201790398A1 (ru) Способы лечения заболевания печени
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201391018A1 (ru) Препараты иммуносупрессантов
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112017006425B8 (pt) Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
BR112018005843A2 (pt) inibidores de calicreína de plasma humano
EA201992149A1 (ru) Комбинация активных ингредиентов, содержащие ее композиции и их применение в лечении саркопении
CL2016002951A1 (es) Combinación farmacéutica para el tratamiento y prevención de la hipertensión arterial y disfunción vascular
BR112018001537A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratamento e para prevenção de uma infecção por hiv em um indivíduo, e, uso de um composto ou sal

Legal Events

Date Code Title Description
FB Suspension of granting procedure